BOI

FR0000061129

Pharmaceuticals

Market Closed - Euronext Paris Other stock markets 11:35:26 2024-04-19 am EDT			5-day change	1st Jan Change
33.8 ^EUR	+0.30%		-1.02%	-15.96%

Feb. 02	Boiron: nearly 600,000 shares tendered to the OPAS	CF
Jan. 11	Boiron: OPAS open from January 11 to 31	CF

Boiron SA Reports Group Earnings Results for the Year Ended December 31, 2018

March 13, 2019 at 01:30 pm EDT

Boiron SA reported group earnings results for the year ended December 31, 2018. For the year, the company reported sales of €604,212,000 against €617,540,000 a year ago. Operating income was €106,022,000 against €124,981,000 a year ago. Net income - group share was €57,459,000 against €78,243,000 a year ago.

Latest news about BOIRON

Boiron: nearly 600,000 shares tendered to the OPAS	Feb. 02	CF
Boiron: OPAS open from January 11 to 31	Jan. 11	CF
Boiron SA Reports Earnings Results for the Half Year Ended June 30, 2023	23-09-10	CI
Oddo BHF Raises Boiron PT, Maintains Outperform Rating	23-09-07	MT
Boiron SAÂ Board intends to launch an Equity Buyback onÂ July 4, 2023.	23-07-04	CI
Boiron SA Reports Earnings Results for the Full Year Ended December 31, 2022	23-03-22	CI
Boiron SA Recommends Dividend, Payable on June 3, 2023	23-03-20	CI
Boiron SA Reports Earnings Results for the Half Year Ended June 30, 2022	22-09-15	CI
Global markets live: Novartis, Tesla, Disney, Sony, Walmart...	22-06-29
Galenica's Verfora To Take Over Distribution Of Boiron Products In Switzerland	22-06-29	MT
Boiron SA's Equity Buyback announced on February 7, 2022 has expired.	22-05-18	CI
Boiron SA Reports Earnings Results for the Full Year Ended December 31, 2021	22-03-10	CI
Boiron SA completed the acquisition of 70% stake in Abbi.	22-02-27	CI
Boiron SA commences an Equity Buyback Plan for 1,727,496 shares, representing 9.85% for €87.73 million, under the authorization approved on May 27, 2021.	22-02-07	CI
Boiron SA signed an agreement to acquire 70% stake in Abbi for €1.8 million.	22-01-19	CI
Boiron Sa Reports Earnings Results for the Half Year Ended June 30, 2021	21-09-08	CI
Boiron SA Reports Earnings Results for the Full Year Ended December 31, 2020	21-04-09	CI
French Agency for the Safety of Medicines and Health Products Selects Emmac Life Sciences Group in Partnership with Boiron as the Suppliers for the Forthcoming French Medical Cannabis Trial	21-01-26	CI
GLOBAL MARKETS LIVE: LVMH, Lululemon, Apple, Boeing…	20-09-09
Boiron SA Announces Unaudited Consolidated Earnings Results for the Year Ended December 31, 2019	20-04-21	CI
Boiron Sa Reports Earnings Results for the Half Year Ended June 30, 2019	19-09-03	CI
Boiron SA Reports Group Earnings Results for the Year Ended December 31, 2018	19-03-13	CI
GLOBAL MARKETS LIVE: Boeing, Blackstone, Adidas, Spotify, Apple…	19-03-13
Boiron SA Announces Proposes Dividend	18-12-11	CI
Boiron SA's Equity Buyback announced on March 30, 2018 has expired.	18-11-16	CI

Chart BOIRON

Duration

Period

More charts

Company Profile

Laboratoires BOIRON was founded in France almost a century ago, under the impetus of homeopathic doctors who wanted to benefit from the most reliable medicines possible. Homeopathic medicines have many advantages in that they can be prescribed and advised in first line whenever relevant, in both urban and hospital settings. All actions aim to contribute to major public health issues. Homeopathic medicines are obtained from substances called homeopathic strains, according to a manufacturing process described in the pharmacopoeia. These strains can be of plant, animal, mineral or chemical origin. There are two main families of homeopathic medicines: common name homeopathic medicines and brand name homeopathic medicines (specialties). BOIRON group centralizes its production and logistics in France. It also has 26 wholly-owned or leased distribution facilities in France and various offices in the countries where it has subsidiaries. Net sales are distributed geographically as follows: France (52.4%), Europe (22.5%), North America (22.6%) and other (2.5%).

Sector

Pharmaceuticals

Calendar

2024-05-22 - Shareholders Meeting

More about the company

Income Statement Evolution

More financial data

Ratings for BOIRON

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

33.7 EUR

Average target price

39.6 EUR

Spread / Average Target

+17.51%

Consensus

EPS Revisions

Estimates Revisions

Quarterly revenue - Rate of surprise

Company calendar

Sector Alternative Medicine

	1st Jan change	Capi.
BOIRON	-15.96%	624M
DONG-E-E-JIAO CO.,LTD.	+40.86%	6.16B
SHIJIAZHUANG YILING PHARMACEUTICAL CO., LTD.	-16.30%	4.49B
TASLY PHARMACEUTICAL GROUP CO., LTD	-9.93%	3.17B
TIANJIN PHARMACEUTICAL DA REN TANG GROUP CORPORATION LIMITED	-1.58%	3.01B
SHANDONG BUCHANG PHARMACEUTICALS CO., LTD.	-1.70%	2.57B
HENAN LINGRUI PHARMACEUTICAL CO., LTD.	+37.23%	1.8B
GUANGYUYUAN CHINESE HERBAL MEDICINE CO., LTD.	-12.78%	1.62B
TIBET CHEEZHENG TIBETAN MEDICINE CO., LTD.	+1.02%	1.56B
TIANJIN CHASE SUN PHARMACEUTICAL CO.,LTD	-12.97%	1.53B

Alternative Medicine

BOIRON

Equities

BOI

FR0000061129

Pharmaceuticals

Boiron SA Reports Group Earnings Results for the Year Ended December 31, 2018

Latest news about BOIRON

Chart BOIRON

Company Profile

Income Statement Evolution

Ratings for BOIRON

Analysts' Consensus

EPS Revisions

Quarterly revenue - Rate of surprise

Sector Alternative Medicine